01—Abstract
Summary
Summary of the 8-K filed March 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. has announced a significant restructuring of its business segments, effective from November 2024, which is being formally disclosed in this 8-K filing.
The company has reorganized into three new reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. This change is driven by a strategy to enhance market focus and customer centricity. Investors should note that this filing primarily serves to provide recast financial information for the company's Annual Report on Form 10-K for the year ended October 31, 2024, to reflect these new segment structures.
It does not introduce new financial results or update the Management's Discussion and Analysis for events after the 10-K filing date. For the most current financial performance and forward-looking information, investors are directed to Agilent's subsequent Quarterly Report on Form 10-Q for the period ended January 31, 2025, and other SEC filings.
02—Key points
Key Highlights
- Agilent Technologies has reorganized its business segments to align with a market-focused, customer-centric strategy.
- The company now operates under three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
- The new Life Sciences and Diagnostics Markets segment combines former Diagnostics and Genomics with specific instrument platforms.
- The Agilent CrossLab segment now includes chemistries, supplies, laboratory automation, and software from previous segments.
- The Applied Markets segment comprises the remaining divisions, including gas chromatography, mass spectrometry, and spectroscopy.
- This 8-K filing provides recast information for Agilent's 2024 10-K to reflect these segment changes.
- Investors are advised to consult the most recent 10-Q filing for current financial performance and updates beyond the 10-K.
03—Questions
Frequently Asked Questions
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to formally announce and provide recast financial information for Agilent's 2024 Annual Report on Form 10-K, reflecting a significant reorganization of its business segments into three new reportable segments.
How has Agilent's business segment structure changed?
Agilent has changed its reporting structure to three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. This reorganization is aimed at supporting a more market-focused and customer-centric strategy.
Does this filing include new financial results or performance updates?
No, this filing does not include new financial results or update the Management's Discussion and Analysis for events occurring after the 2024 10-K filing date. It only provides recast historical information to align with the new segment structure. For current financial performance, investors should refer to the latest 10-Q filing.
Which specific product lines or divisions moved into which new segments?
The Life Sciences and Diagnostics Markets segment combines the former Diagnostics and Genomics segment with liquid chromatography and liquid chromatography mass spectrometry instruments. The Agilent CrossLab segment now houses chemistries and supplies, laboratory automation, and software and informatics. The Applied Markets segment includes gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy, and vacuum divisions.
04—Continue